天堂网www最新版官网,女18毛片,视频区国产亚洲.欧美

Sanofi: Cutting Three Pipeline Programs Sanofi In Q3 2024, Sanofi reported a 15.7% increase in sales to €13.4 billion, driven by vaccine sales. The company removed three studies from its pipeline while achieving key regulatory approvals and positive trial results for several products, including Dupixent.
Pfizer Q3 2024: Oncology Business Grows 31%, Raises Full-Year Revenue Guidance Financial statements Pfizer's Q3 2024 report shows operating revenue rose 32% to $17.7 billion, with total revenue for the year so far at $45.9 billion. The oncology business grew 31%, driven by Talzenna and Padcev. Pfizer raised its full-year guidance to $61-64 billion.
Novartis 2024 Q3: Nuclear Medicine Surpasses $1 Billion, Leqvio Doubles Revenue Novartis Novartis Q3 2024 results: Revenue up 10% to $12.823B with net income soaring by 121%. Major product growth, including Entresto, Cosentyx, and Kesimpta, alongside Kisqali and Pluvicto, drive earnings. Immunology, neuroscience, and oncology sales climb as R&D and new indications expand global reach.
Johnson & Johnson Q3 Report: BCMA CAR-T Sales Reach 2 Billion RMB, 88% Growth Financial statements Johnson & Johnson's Q3 2024 report highlights strong growth in BCMA CAR-T therapy Carvykti, with sales reaching 2 billion RMB, up 88% year-on-year. Total quarterly revenue hit $22.47 billion, driven by innovative pharmaceuticals and medical devices.
Ashland Reports Q3 FY2024 Results: Sales at $544M, Adjusted EBITDA Up 5% Ashland Ashland Inc. announces Q3 FY2024 results with $544 million in sales and a 5% increase in adjusted EBITDA. Despite a decline in Life Sciences, Personal Care saw strong growth. Outlook for Q4 FY2024 projects sales between $530M-$540M.
Symrise Reports Strong 2024 Growth with 6.3% Sales Increase and 20.7% EBITDA Margin Symrise Symrise AG achieves robust 6.3% sales growth to €2.57 billion and a 20.7% EBITDA margin in H1 2024, driven by strong performance in key segments despite global market challenges.
Croda Achieves Stable H1 2024 Results with Strong Cash Flow Despite Life Sciences Challenges Croda Croda reports steady H1 2024 performance, with sales growth in Consumer Care and Industrial Specialties. Strong cash flow and reduced net debt bolster results, despite weaker demand in Life Sciences.
AbbVie Reports Strong Q2 2024 Performance, Adjusts Full-Year EPS Guidance Financial statements AbbVie reports Q2 2024 revenue growth of 4.3% to $14.462 billion, driven by Skyrizi and Rinvoq. Despite robust sales, GAAP EPS fell by 32.5% due to IPR&D expenses. Oncology and Neuroscience portfolios also showed solid gains
Pfizer Q2 2024: 14% Growth in Non-COVID Products, Raises Full-Year Revenue Guidance Financial statements Pfizer reports a 2% revenue increase in Q2 2024, driven by 14% growth in non-COVID products like Seagen and Vyndaqel. Full-year revenue guidance raised to $59.5-$62.5 billion, with adjusted EPS guidance increased to $2.45-$2.65.
Corteva Reports Q2 2024 Earnings and Updates Full-Year Forecast Corteva Corteva reports a 1% increase in Q2 2024 net sales, with Crop Protection volume up 6% and Seed sales rising to $4.33 billion. Operating EBITDA grew by 10%, with a positive outlook for the full year.

< Pre 1...10 11 121314 15 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a